These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2993929)

  • 1. Learning experiences from UNC. Renal autoregulation, drugs, and acute renal failure.
    Blythe WB
    N C Med J; 1985 Jul; 46(7):413-4. PubMed ID: 2993929
    [No Abstract]   [Full Text] [Related]  

  • 2. Renal protection in essential hypertension: how do angiotensin-converting enzyme inhibitors compare with calcium antagonists?
    Bauer JH; Reams GP
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S80-7. PubMed ID: 16989071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nephroprotection by antihypertensive agents.
    Schmieder RE
    J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S55-64. PubMed ID: 7898095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Captopril and renal autoregulation.
    Blythe WB
    N Engl J Med; 1983 Feb; 308(7):390-1. PubMed ID: 6337329
    [No Abstract]   [Full Text] [Related]  

  • 5. Angiotensin converting enzyme inhibition and autoregulation of glomerular filtration.
    Plante GE; Chainey A; Sirois P; Devissaguet M
    J Hypertens Suppl; 1988 Dec; 6(3):S69-73. PubMed ID: 3066878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal effects of calcium antagonists with special reference to manidipine hydrochloride.
    Rodicio JL
    Blood Press Suppl; 1996; 5():10-5. PubMed ID: 8973787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal hemodynamics, converting enzyme inhibitors and calcium antagonists in atheromatous renovascular hypertension.
    Hannedouche T; Godin M; Fillastre JP
    Clin Nephrol; 1987 Nov; 28(5):261-2. PubMed ID: 3427836
    [No Abstract]   [Full Text] [Related]  

  • 8. Calcium antagonists and the kidney.
    Chellingsworth M; Kendall MJ
    J Hum Hypertens; 1987 Jun; 1(1):3-8. PubMed ID: 3334055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Renal protective effects of calcium antagonists].
    Musialik D; Raszeja-Wanic B; Tylarski A
    Pol Merkur Lekarski; 1996 Oct; 1(4):266-70. PubMed ID: 9156942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The renoprotective action of angiotensin-converting enzyme inhibitors in diabetes.
    Ruggenenti P; Remuzzi G
    Exp Nephrol; 1996; 4 Suppl 1():53-60. PubMed ID: 9001898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Renal effects of conversion enzyme inhibitors].
    Füger K; Wienbeck M; Mann J
    Dtsch Med Wochenschr; 1991 Sep; 116(36):1372-3. PubMed ID: 1884679
    [No Abstract]   [Full Text] [Related]  

  • 12. Renal syndromes associated with nonsteroidal antiinflammatory drugs.
    Clive DM; Stoff JS
    N Engl J Med; 1984 Mar; 310(9):563-72. PubMed ID: 6363936
    [No Abstract]   [Full Text] [Related]  

  • 13. A randomized and double-blind comparison of isradipine and spirapril as monotherapy and in combination on the decline in renal function in patients with chronic renal failure and hypertension.
    Petersen LJ; Petersen JR; Talleruphuus U; Møller ML; Ladefoged SD; Mehlsen J; Jensen HA
    Clin Nephrol; 2001 May; 55(5):375-83. PubMed ID: 11393383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonsteroidal antiinflammatory drugs, prostaglandins, and the kidney.
    Rubin SI
    J Am Vet Med Assoc; 1986 May; 188(9):1065-8. PubMed ID: 3086264
    [No Abstract]   [Full Text] [Related]  

  • 15. Calcium antagonists and renal failure progression.
    Robles NR
    Ren Fail; 2008; 30(3):247-55. PubMed ID: 18350443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-converting enzyme inhibition and calcium channel blockade both normalize early hyperfiltration in experimental diabetes, but only the former prevents late renal structural damage.
    Perico N; Amuchastegui CS; Malanchini B; Bertani T; Remuzzi G
    Exp Nephrol; 1994; 2(4):220-8. PubMed ID: 8069658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heart failure, renal function, and angiotensin converting enzyme inhibitors.
    Cleland JG; Dargie HJ
    Kidney Int Suppl; 1987 May; 20():S220-8. PubMed ID: 3037173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects on angiotensin-converting enzyme inhibition on renal hemodynamics in renal artery stenosis.
    Levenson DJ; Dzau VJ
    Kidney Int Suppl; 1987 May; 20():S173-9. PubMed ID: 3037167
    [No Abstract]   [Full Text] [Related]  

  • 19. Vasoactive drugs and the importance of renal perfusion pressure.
    Bersten AD; Holt AW
    New Horiz; 1995 Nov; 3(4):650-61. PubMed ID: 8574595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonpeptide angiotensin II receptor antagonists: potential advantages over ACE inhibitors.
    Brooks DP; DePalma PD; Fredrickson TA; Spielman WS; Ruffolo RR
    Proc West Pharmacol Soc; 1993; 36():25-8. PubMed ID: 8378384
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.